Informative censoring of surrogate end-point data in phase 3 oncology trials
Kaplan –Meier (K-M) analysis, the cornerstone of cancer clinical trial interpretation, assumes that censored patients are no more or less likely to experience an event than those followed. We sought to investigate the patterns of censoring in surrogate end-points of oncology randomised controlled trials (RCTs) and examine the relationship between censoring in practice-changing treatments that failed to demonstrate survival gain.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Shai Gilboa, Yarden Pras, Aviv Mataraso, David Bomze, Gal Markel, Tomer Meirson Tags: Original Research Source Type: research